ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO923

Clinical Characteristics Associated With Higher Mayo Clinic Chronicity Score

Session Information

Category: CKD (Non-Dialysis)

  • 2201 CKD (Non-Dialysis): Epidemiology‚ Risk Factors‚ and Prevention


  • Deleersnijder, Dries, Katholieke Universiteit Leuven, Leuven, Belgium
  • Cleenders, Evert Jan, Katholieke Universiteit Leuven, Leuven, Belgium
  • Laurens, Wim, AZ Nikolaas, Sint-Niklaas, Belgium
  • Dendooven, Amélie, Universitair Ziekenhuis Gent, Ghent, Belgium
  • De Meester, Johan MJ, AZ Nikolaas, Sint-Niklaas, Belgium
  • Sprangers, Ben, Katholieke Universiteit Leuven, Leuven, Belgium

Group or Team Name

  • FCGG collaborative group

The Mayo Clinic Chronicity Score (MCCS) is a standardized scoring system to uniformly grade chronic changes in kidney biopsies. The Flemish Collaborative Glomerulonephritis Group (FCGG) registry is the first multicenter native kidney biopsy registry in Europe to systematically collect MCCS in all included biopsies.


From 2018-2019, MCCS was available for 890 included adult biopsies (each containing ≥10 glomeruli). The association between MCCS and sex, age, kidney injury, proteinuria and nephrological diagnosis was determined using a multiple linear regression model. A linear mixed-effect model showed no significant confounding pathologist-effect.


Sex was not associated with significant changes in MCCS (Table 1). Increasing patient age was associated with only mild increase in MCCS. When compared to patients with normal kidney function, chronic kidney disease (CKD) was associated with a large MCCS increase (2.596, 95% CI [2.079, 3.112], P<0.001). Nephrotic-range proteinuria was associated with a smaller MCCS increase (0.982 (95% CI [0.520, 1.444], P<0.001), likely because it may reflect both disease activity and chronicity. When compared to IgA nephropathy, diagnoses of FSGS, nephrosclerosis, diabetic kidney disease and hyperoxaluria/hypercalcemic nephropathy were all associated with significantly higher MCCS.


CKD and diagnoses of FSGS, nephrosclerosis, diabetic kidney disease and hyperoxaluria/hypercalcemic nephropathy were associated with highest degrees of chronicity in native kidney biopsies in Flanders, Belgium.

The ß indicates the change in estimated MCCS, P-values < 0.05 considered significant (bold).
a: only diagnoses with a significant result for ß shown; b: Fabry disease and tuberous sclerosis; c: enteric hyperoxaluria and hypercalcemic nephropathy; d: non-specific nephrotoxicity and nephropathy due to analgesic drugs, lithium or tacrolimus.